Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), By Treatment, By Distribution Channels, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Savory Ingredients Market Growth & Trends
The global savory ingredients market size is anticipated to reach USD 15.62 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2024 to 2030. Savory ingredients are widely used as seasoning and flavoring agents in the food industry.
Growing disposable income has increased the consumption of time-saving food product, which is projected to boost the market growth over the coming years. The growing usage of savory ingredients in the food service industry is also expected to propel market growth.
Savory ingredients are used in the animal feed & pet food industry to enhance food flavors. The growing demand for packaged pet food in Asia Pacific is anticipated to drive market demand over the coming years.
Companies such as DSM, Kerry Group, Givaudan, Diana, and Lesaffre have adopted acquisition strategies to enhance their product offerings and regional presence. This approach has helped companies acquire distribution centers and diversify their offerings across many end-use application markets.
Savory Ingredients Market Report Highlights
Savory Ingredients Market Growth & Trends
The global savory ingredients market size is anticipated to reach USD 15.62 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.7% from 2024 to 2030. Savory ingredients are widely used as seasoning and flavoring agents in the food industry.
Growing disposable income has increased the consumption of time-saving food product, which is projected to boost the market growth over the coming years. The growing usage of savory ingredients in the food service industry is also expected to propel market growth.
Savory ingredients are used in the animal feed & pet food industry to enhance food flavors. The growing demand for packaged pet food in Asia Pacific is anticipated to drive market demand over the coming years.
Companies such as DSM, Kerry Group, Givaudan, Diana, and Lesaffre have adopted acquisition strategies to enhance their product offerings and regional presence. This approach has helped companies acquire distribution centers and diversify their offerings across many end-use application markets.
Savory Ingredients Market Report Highlights
- The MSG segment accounted for the largest market revenue share of 61.1% in 2023. MSG is extensively used in the food industry due to its ability to enhance flavor, making it a prevalent additive in processed and packaged foods.
- The natural segment accounted for the largest market revenue share in 2023. Natural ingredients are perceived as healthier alternatives to artificial additives, contributing to a balanced diet without the associated risks of synthetic chemicals.
- The powder segment accounted for the largest market revenue share in 2023. Powdered savory ingredients have a longer shelf life. The drying process removes moisture, which stops the growth of bacteria and mold.
- The food segment accounted for the largest market revenue share in 2023. The growing need for quick meal solutions has increased demand for ready-to-eat food, snacks, and packaged foods.
- Asia Pacific savory ingredients market accounted for the largest revenue share of 70.7% in 2023. Consumers are pursuing foods that offer additional health benefits beyond basic nutrition, such as improved digestion, better immune function, or enhanced energy levels.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. SCHIZOPHRENIA DRUGS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Schizophrenia Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. SCHIZOPHRENIA DRUGS MARKET: CLASS ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
4.2.1. Second-Generation Antipsychotics
4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Risperdal (Risperidone)
4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Invega (Paliperidone)
4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.4. Zyprexa (Olanzapine)
4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.5. Geodon (Ziprasidone)
4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.6. Seroquel (Quetiapine)
4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.7. Latuda (Lurasidone)
4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.8. Aristada (Aripiprazole Lauroxil)
4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.9. Fanapt (Iloperidone)
4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.10. Saphris (Asenapine)
4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.11. Vraylar (Cariprazine)
4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Third-Generation Antipsychotics
4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. Abilify (Aripiprazole)
4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Others
4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. First-Generation Antipsychotics
4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Generics
4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. SCHIZOPHRENIA DRUGS MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
5.2.1. Oral Antipsychotics
5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Injectable Antipsychotics
5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. SCHIZOPHRENIA DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
6.2.1. Hospital Pharmacies
6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. Retail Pharmacies
6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Online Pharmacies
6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Others
6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. SCHIZOPHRENIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Johnson & Johnson
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. AstraZeneca
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Sumitomo Dainippon
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Eli Lilly & Company
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Alkermes
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Vanda Pharma
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Allergan
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Pfizer
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. H. Lundbeck A/S
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. SCHIZOPHRENIA DRUGS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Schizophrenia Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. SCHIZOPHRENIA DRUGS MARKET: CLASS ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
4.2.1. Second-Generation Antipsychotics
4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Risperdal (Risperidone)
4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Invega (Paliperidone)
4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.4. Zyprexa (Olanzapine)
4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.5. Geodon (Ziprasidone)
4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.6. Seroquel (Quetiapine)
4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.7. Latuda (Lurasidone)
4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.8. Aristada (Aripiprazole Lauroxil)
4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.9. Fanapt (Iloperidone)
4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.10. Saphris (Asenapine)
4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.11. Vraylar (Cariprazine)
4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Third-Generation Antipsychotics
4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. Abilify (Aripiprazole)
4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3. Others
4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. First-Generation Antipsychotics
4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Generics
4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. SCHIZOPHRENIA DRUGS MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
5.2.1. Oral Antipsychotics
5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Injectable Antipsychotics
5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. SCHIZOPHRENIA DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
6.2.1. Hospital Pharmacies
6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. Retail Pharmacies
6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Online Pharmacies
6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Others
6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. SCHIZOPHRENIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Johnson & Johnson
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. AstraZeneca
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Sumitomo Dainippon
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Eli Lilly & Company
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Alkermes
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Vanda Pharma
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Allergan
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Pfizer
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. H. Lundbeck A/S
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
